|
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
Mar 2019 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes |
Jul 2020 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
Rewriting the rules for care of MDS and AML patients in the time of COVID-19 |
Apr 2020 |
Leukemia Research Reports |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy |
Jan 2024 |
Mediterranean Journal of Hematology and Infectious Diseases |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
TERC haploid cell reprogramming: a novel therapeutic strategy for aplastic anemia |
Jun 2023 |
Molecular Medicine |
Aplastic Anemia |
|
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
Mar 2019 |
National Cancer Institute |
Myelodysplastic Syndromes (MDS) |
|
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes |
Aug 2020 |
Nature Medicine |
Myelodysplastic Syndromes (MDS) |
|
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
Oct 2023 |
Oncologist |
Myelodysplastic Syndromes (MDS) |
|
Experience of life quality from patients with aplastic anemia: a descriptive qualitative study |
Dec 2023 |
Orphanet Journal of Rare Diseases |
Aplastic Anemia |
|
Myelodysplastic Syndromes Treatment (PDQ®): Health Professional Version |
Sep 2024 |
PDQ Cancer Information Summaries |
Myelodysplastic Syndromes (MDS) |
